Salah-Eddin Al-Batran

Salah-Eddin Al-Batran

Auto-generated profile, based on publicly available information

Salah-Eddin Al-Batran

Institute of Clinical Research UCT-University Cancer Center, Frankfurt, Germany

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
HFHenner F. Farin
Henner F. Farin
MMMohammed H. Mosa
Mohammed H. Mosa
BNBenardina Ndreshkjana
Benardina Ndreshkjana
BGBritta M. Grebbin
Britta M. Grebbin
BRBirgit Ritter
Birgit Ritter
FGFlorian Greten
Florian Greten
In colorectal cancers, the tumor microenvironment plays a key role in prognosis and therapy efficacy. Patient-derived tumor organoids (PDTO) show enormous potential for preclinical testing; however, cultured tumor cells lose important characteristics, including the consensus molecular subtypes (CMS). To better reflect the cellular heterogeneity, we established the colorectal cancer organoid–stroma biobank of matched PDTOs and cancer-associated fibroblasts (CAF) from 30 patients. Context-specific phenotyping showed that xenotransplantation or coculture with CAFs improves the transcriptomic fidelity and instructs subtype-specific stromal gene expression. Furthermore, functional profiling in coculture exposed CMS4-specific therapeutic resistance to gefitinib and SN-38 and prognostic expression signatures. Chemogenomic library screening identified patient- and therapy-dependent mechanisms of stromal resistance including MET as a common target. Our results demonstrate that colorectal cancer phenotypes are encrypted in the cancer epithelium in a plastic fashion that strongly depends on the context. Consequently, CAFs are essential for a faithful representation of molecular subtypes and therapy responses ex vivo. Significance: Systematic characterization of the organoid–stroma biobank provides a resource for context dependency in colorectal cancer. We demonstrate a colorectal cancer subtype memory of PDTOs that is independent of specific driver mutations. Our data underscore the importance of functional profiling in cocultures for improved preclinical testing and identification of stromal resistance mechanisms. This article is featured in Selected Articles from This Issue, p. 2109

27 April 2020 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
SLSylvie Lorenzen
Sylvie Lorenzen
JKJorge Riera Knorrenschild
Jorge Riera Knorrenschild
CPClaudia Pauligk
Claudia Pauligk
SHSusanna Hegewisch‐Becker
Susanna Hegewisch‐Becker
JSJörg Seraphin
Jörg Seraphin
SASalah‐Eddin Al‐Batran
Salah‐Eddin Al‐Batran
The RADPAC trial evaluated paclitaxel with everolimus in patients with advanced gastroesophageal cancer (GEC) who have progressed after therapy with a fluoropyrimidine/platinum‐containing regimen. Patients were randomly assigned to receive paclitaxel (80 mg/m2) on day 1, 8 and 15 plus everolimus (10 mg daily, arm B) d1‐d28 or placebo (arm A), repeated every 28 days. Primary end point was overall survival (OS). Efficacy was assessed in the intention‐to‐treat population and safety in all patients who received at least one dose of treatment. This trial is registered with ClinicalTrials.gov, number NCT01248403. Between October 2011 and September 2015, 300 patients (median age: 62 years; median lines prior therapy: 2; 47.7% of patients had prior taxane therapy) were randomly assigned (arm A, 150, arm B, 150). In the intention to treat population, there was no significant difference in progression‐free survival (PFS; everolimus, 2.2 vs placebo, 2.07 months, HR 0.88, P = .3) or OS (everolimus, 6.1 vs placebo, 5.0 months, HR 0.93, P = .54). For patients with prior taxane use, everolimus improved PFS (everolimus, 2.7 vs placebo 1.8 months, HR 0.69, P = .03) and OS (everolimus, 5.8 vs placebo 3.9 months, HR 0.73, P = .07). Combination of paclitaxel and everolimus was associated with significantly more grade 3‐5 mucositis (13.3% vs 0.7%; P < .001). The addition of everolimus to paclitaxel did not improve outcomes in pretreated metastatic gastric/gastroesophageal junction (GEJ) cancer. Activity was seen in the taxane pretreated group. Additional biomarker studies are planned to look for subgroups that may have a benefit.

20 May 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
YJYelena Y. Janjigian
Yelena Y. Janjigian
ECEric Van Cutsem
Eric Van Cutsem
KMKei Muro
Kei Muro
ZWZev A. Wainberg
Zev A. Wainberg
SASalah-Eddin Al-Batran
Salah-Eddin Al-Batran
Josep TaberneroJosep Tabernero
Josep Tabernero
TPS4151 Background: Gastric and gastroesophageal junction cancers (GC, GEJC) are the fifth most common cancer types and the third leading cause of cancer-related deaths globally (Globocan 2020). Standard of care for resectable GC/GEJC includes neoadjuvant-adjuvant FLOT chemotherapy (5-fluorouracil + leucovorin + oxaliplatin + docetaxel) combined with surgery and lymph node dissection for some regions of the world. While treatment advances have improved survival, the 5-year recurrence rate remains high and 5-year overall survival (OS) is poor for patients with resectable disease. Evidence suggests cytotoxic chemotherapy can promote antitumor immunity, thus the combination of immune checkpoint inhibitors, such as durvalumab (an anti–PD-L1 antibody), with cytotoxic chemotherapy may result in increased efficacy (Yu et al. Cancer Lett. 2019; Li et al. Mol Cancer. 2021). MATTERHORN (NCT04592913) is a phase 3, multicenter study evaluating the efficacy and safety of neoadjuvant-adjuvant durvalumab or placebo with FLOT followed by adjuvant durvalumab or placebo in patients with resectable GC/GEJC. Methods: Approximately 900 adult patients will be randomized 1:1 to Arm A or Arm B for 2 neoadjuvant and 2 adjuvant cycles (single cycle defined as durvalumab or placebo every 4 weeks [Q4W] + FLOT [Q2W × 2]); followed by durvalumab or placebo Q4W for 10 cycles. Eligible patients must have histologically confirmed, resectable, stage II or higher GC or GEJC not treated with anticancer therapy, ECOG performance status 0 or 1, and adequate organ function. Complete surgical resection of the primary tumor must be achievable. A tumor tissue sample will be taken at screening or <3 months prior to enrollment. Key exclusion criteria are any prior immune-mediated therapy, peritoneal dissemination or distant metastasis, (adeno)squamous cell carcinoma, or gastrointestinal stromal tumor. The primary endpoint is event-free survival (EFS) assessed by blinded independent central radiology review (BICR) and/or local pathology testing. Secondary endpoints include OS and pathological complete response rate (pCR). Safety and tolerability will be evaluated by adverse events, vital signs, laboratory parameters, and electrocardiogram. Enrollment is ongoing. Funding: AstraZeneca. Clinical trial information: NCT04592913.

20 May 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PTPeter Thuss-Patience
Peter Thuss-Patience
SASalah-Eddin Al-Batran
Salah-Eddin Al-Batran
Jens SivekeJens Siveke
Jens Siveke
NHNils Homann
Nils Homann
PMPeter Malfertheiner
Peter Malfertheiner
UPUwe Pichlmeier
Uwe Pichlmeier
4033 Background: Pazopanib is an oral tyrosine kinase inhibitor which selectively inhibits angiogenesis via VEGFR-1, -2, -3, ckit and PDGF-R. Recent positive trials show that angiogenesis is an effective target in gastric cancer. In this randomized phase II trial we treated patients (pts) with FLO +/- Pazopanib. Methods: Pts with metastatic or locally advanced gastric or gastro-esophageal junction adenocarcinoma, HER2 negative and with measurable disease were randomized in a 2:1 ratio to 5-FU (2,6g/m²/24h, d1) + Leukovorin (200mg/m², d1) + Oxaliplatin (85mg/m², d1) (FLO) + Pazopanib (800mg/d d1-14, q2w) (arm A) or the same chemotherapy without Pazopanib (arm B). Analysis was planned with a Simon Minimax design with PFS rate at 6 month in arm A as the primary endpoint expecting a minimum of 40% of pts progression free. Results: 87 pts were randomized, eligible and evaluable were 51 pts in arm A and 27 in arm B. Pts characteristics in % (arm A/arm B): male: 72/63%, female: 28/37%; median age: 65/60 yrs; ECO...

20 May 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
USUgur Sahin
Ugur Sahin
SASalah-Eddin Al-Batran
Salah-Eddin Al-Batran
WHWael Hozaeel
Wael Hozaeel
ZZZanete Zvirbule
Zanete Zvirbule
JFJens Freiberg-Richter
Jens Freiberg-Richter
OTOezlem Tureci
Oezlem Tureci
E15079 Background: IMAB362 is the first-in-class monoclonal antibody against the tight junction molecule claudin 18.2 (CLDN18.2) executing its antitumor activity via 4 highly potent modes of action (antibody-dependent cellular cytotoxicity [ADCC], complement-dependent cytotoxicity, proliferation inhibition, apoptosis). Previous in vitro and in vivo data showed that ZA and IL-2 augmented IMAB362’s antitumor activity by affecting immune-related mechanisms. This exploratory Phase I trial aimed to evaluate IMAB362 plus ZA/IL-2 in pts with CLDN18.2+GEC. Methods: Pts with CLDN18.2+ chemo-refractory GEC received IMAB362 (800 in cycle [cy] 1, followed by 600 mg/m2 in subsequent cy, IV q3w) plus ZA (4 mg, IV, day 1 of cy 1 & 3) in arm 1; IMAB362, ZA plus low IL-2 (1×106 IU, s.c., days 1–3 of cy 1 & 3) in arm 2; IMAB362, ZA plus intermediate IL-2 (3×106 IU s.c., days 1–3 of cy 1 & 3) in arm 3; and IMAB362 alone in arm 4. Primary endpoints are biomarkers to assess immunomodulatory effects of treatments (modulation o...

8 March 2024 in Annals of Surgical Oncology
Verified
Journal Article
Open access
PDF file
TGThorsten O. Goetze
Thorsten O. Goetze
ARAlexander Reichart
Alexander Reichart
UBUlli Simone Bankstahl
Ulli Simone Bankstahl
CPClaudia Pauligk
Claudia Pauligk
MLMaria Loose
Maria Loose
SASalah-Eddin Al-Batran
Salah-Eddin Al-Batran
Background: Although addition of adjuvant chemotherapy is the current standard, the prognosis of pancreatic cancers still remains poor. The NEPAFOX trial evaluated perioperative treatment with FOLFIRINOX in resectable pancreatic cancer. Patients and Methods: This multicenter phase II trial randomized patients with resectable or borderline resectable pancreatic cancer without metastases into arm (A,) upfront surgery plus adjuvant gemcitabine, or arm (B,) perioperative FOLFIRINOX. The primary endpoint was overall survival (OS). Results: Owing to poor accrual, recruitment was prematurely stopped after randomization of 40 of the planned 126 patients (A: 21, B: 19). Overall, approximately three-quarters were classified as primarily resectable (A: 16, B: 15), and the remaining patients were classified as borderline resectable (A: 5, B: 4). Of the 12 evaluable patients, 3 achieved partial response under neoadjuvant FOLFIRINOX. Of the 21 patients in arm A and 19 patients in arm B, 17 and 7 underwent curative surgery, and R0-resection was achieved in 77% and 71%, respectively. Perioperative morbidity occurred in 72% in arm A and 46% in arm B, whereas non-surgical toxicity was comparable in both arms. Median RFS/PFS was almost doubled in arm B (14.1 months) compared with arm A (8.4 months) in the population with surgical resection, whereas median OS was comparable between both arms. Conclusions: Although the analysis was only descriptive owing to small patient numbers, no safety issues regarding surgical complications were observed in the perioperative FOLFIRINOX arm. Thus, considering the small number of patients, perioperative treatment approach appears feasible and potentially effective in well-selected cohorts of patients. In pancreatic cancer, patient selection before initiation of neoadjuvant therapy appears to be critical.